Cancer Precision Medicine
Precision medicine is a treatment approach customised to each individual patient. Because no two cancers are precisely alike, therapies often need to be tailored to specific tumours and patients to be effective. In cancer, precision medicine uses specific information about a person’s tumour to help make a diagnosis, plan treatment, monitor treatment response, or make a prognosis.
In the research programme Cancer Precision Medicine, we aim to understand how factors such as genetics, epigenetics, molecular mechanisms, proteins, biomarkers, cellular processes, tumour biology and epidemiology can form a basis to find the best approach to prevent or treat the disease. Our research ranges all the way from bench to bedside.
Panagiotis Baliakas – Molecular genetics of hematological malignancies
Johan Botling – Molecular tumour pathology
Jan Dumanski – Molecular oncology
Ingrid Glimelius – Clinical, epidemiological and tumour biology studies of different cancer forms
Helena Jernberg Wiklund – Targeting epigenetic regulators to develop novel therapeutic strategies and precision medicine in human haematological cancers
Birgitta Johansson – Caring sciences in oncology care
Cecilia Lindskog Bergström – A spatio-temporal single-cell type map of human tissues
Magnus Lindskog – Clinical and epidemiological studies to identify optimal treatment strategies for chemo-resistant cancers
Marika Nestor – Novel cancer-targeting strategies for improved molecular radiotherapy
Peter Nygren – New and individualised cancer treatment
Tobias Sjöblom – Finding and understanding cancer-causing molecular alterations
Bo Stenerlöw – Radiation biology and DNA repair
Vladimir Tolmachev – Scaffold protein-based radionuclide tumour targeting